Company Registration No. 15127126 (England and Wales)
UK Health Solutions Holdings Limited
Unaudited financial statements
for the year ended 31 December 2024
Pages for filing with the registrar
UK Health Solutions Holdings Limited
Contents
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 6
UK Health Solutions Holdings Limited
Statement of financial position
As at 31 December 2024
31 December 2024
1
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
3
2,092,530
2,092,530
Current assets
Debtors
4
5,262
37,537
Creditors: amounts falling due within one year
5
(2,282,019)
(2,146,094)
Net current liabilities
(2,276,757)
(2,108,557)
Net liabilities
(184,227)
(16,027)
Capital and reserves
Called up share capital
6
1,000
1,000
Profit and loss reserves
(185,227)
(17,027)
Total equity
(184,227)
(16,027)

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 25 March 2025 and are signed on its behalf by:
Christopher Kurt-Gabel
Director
Company Registration No. 15127126
UK Health Solutions Holdings Limited
Statement of changes in equity
For the year ended 31 December 2024
2
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 10 September 2023
-
0
-
0
-
Period ended 31 December 2023:
Loss and total comprehensive income
-
(17,027)
(17,027)
Issue of share capital
6
1,000
-
1,000
Balance at 31 December 2023
1,000
(17,027)
(16,027)
Year ended 31 December 2024:
Loss and total comprehensive income
-
(168,200)
(168,200)
Balance at 31 December 2024
1,000
(185,227)
(184,227)
UK Health Solutions Holdings Limited
Notes to the financial statements
For the year ended 31 December 2024
3
1
Accounting policies
Company information

UK Health Solutions Holdings Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 2 Lysander Mews, Lysander Grove, London, N19 3QP.

1.1
Reporting period

The company was incorporated on 10 September 2023 and the prior period figures present its first period of accounts to 31 December 2023.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Fixed asset investments

Interests in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

UK Health Solutions Holdings Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
1
Accounting policies (continued)
4
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
-
0
-
0
3
Fixed asset investments
2024
2023
£
£
Shares in group undertakings and participating interests
2,092,530
2,092,530
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Other debtors
5,262
37,537
UK Health Solutions Holdings Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
5
5
Creditors: amounts falling due within one year
2024
2023
£
£
Other borrowings
1,899,380
1,899,380
Amounts owed to group undertakings
351,599
219,827
Other creditors
1,388
9,831
Accruals and deferred income
29,652
17,056
2,282,019
2,146,094

Included within other borrowings is £400,000 due to Director Christopher Kurt-Gabel. Interest accrues at 5%.

 

The remaining balance within other borrowings accrues interest between 5% and 10%.

 

Other borrowings do not carry any fixed repayment terms, and are not secured.

 

During the year, a floating charge has been registered over this company as a result of the secured borrowings of its subsidiary.

UK Health Solutions Holdings Limited
Notes to the financial statements (continued)
For the year ended 31 December 2024
6
6
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary Shares of 1p each
55,250
55,250
553
553
B Ordinary Shares of 1p each
44,750
44,750
447
447
100,000
100,000
1,000
1,000

Prescribed particulars in respect to 55,250 A Ordinary Shares of 1p

All shares issues are non-redeemable and rank equally to shares of the same class in terms of each of rights to take part in all approved dividend distributions, voting rights - each share being entitled to one vote and rights to participate in any distribution of capital on winding up of the company.

 

Prescribed particulars in respect to 44,750 B Ordinary Shares of 1p

All shares issues are non-redeemable and rank equally to shares of the same class in terms of each of rights to take part in all approved dividend distributions, voting rights - each share being entitled to one vote and rights to participate in any distribution of capital on winding up of the company.

7
Related party transactions

Management fees have been charged to a subsidiary of UK Health Solutions Holdings Limited of £61,872 (2023: £5,075) during the period.

 

Management fees of £61,842 (2023: £5,075) have been paid during the period to a company with common directorship.

2024-12-312024-01-01false26 March 2025CCH SoftwareCCH Accounts Production 2024.210No description of principal activityMr A J StubbsChristopher Kurt-Gabelfalsefalse151271262024-01-012024-12-31151271262024-12-31151271262023-12-3115127126core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3115127126core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3115127126core:CurrentFinancialInstruments2024-12-3115127126core:CurrentFinancialInstruments2023-12-3115127126core:ShareCapital2024-12-3115127126core:ShareCapital2023-12-3115127126core:RetainedEarningsAccumulatedLosses2024-12-3115127126core:RetainedEarningsAccumulatedLosses2023-12-3115127126core:ShareCapital2023-09-0915127126core:RetainedEarningsAccumulatedLosses2023-09-0915127126core:ShareCapitalOrdinaryShares2024-12-3115127126core:ShareCapitalOrdinaryShares2023-12-3115127126bus:Director22024-01-012024-12-3115127126core:RetainedEarningsAccumulatedLosses2023-09-102023-12-31151271262023-09-102023-12-3115127126core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3115127126core:ShareCapital2023-09-102023-12-3115127126core:WithinOneYear2024-12-3115127126core:WithinOneYear2023-12-3115127126bus:PrivateLimitedCompanyLtd2024-01-012024-12-3115127126bus:SmallCompaniesRegimeForAccounts2024-01-012024-12-3115127126bus:FRS1022024-01-012024-12-3115127126bus:AuditExemptWithAccountantsReport2024-01-012024-12-3115127126bus:Director12024-01-012024-12-3115127126bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP